{"altmetric_id":4691817,"citation":{"altmetric_jid":"clinicaltrialsgov","authors":["Merck KGaA"],"first_seen_on":"2015-10-28T14:27:12+00:00","issns":[],"journal":"ClinicalTrials.gov","last_mentioned_on":1450385589,"links":["http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02255110?rcv_d=14&show_rss=Y&term=clinical+trials","https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02255110?term=evofosfamide&amp;rank=1","https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02255110?term=evofosfamide&rank=1"],"nct_id":"NCT02255110","pubdate":"2014-09-30T00:00:00+00:00","publisher":"ClinicalTrials.gov","title":"A Japanese Trial of TH-302 in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma","type":"clinical_trial_study_record"},"altmetric_score":{"score":9.5,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":9.5},"context_for_score":{"all":{"total_number_of_other_articles":6787729,"mean":6.1724472011828,"rank":678664,"this_scored_higher_than_pct":89,"this_scored_higher_than":6099867,"rank_type":"exact","sample_size":6787729,"percentile":89},"similar_age_3m":{"total_number_of_other_articles":236284,"mean":9.4354852528536,"rank":34302,"this_scored_higher_than_pct":85,"this_scored_higher_than":201411,"rank_type":"exact","sample_size":236284,"percentile":85},"this_journal":{"total_number_of_other_articles":17057,"mean":9.4901502110694,"rank":2164,"this_scored_higher_than_pct":86,"this_scored_higher_than":14789,"rank_type":"exact","sample_size":17057,"percentile":86},"similar_age_this_journal_3m":{"total_number_of_other_articles":880,"mean":13.150866894198,"rank":121,"this_scored_higher_than_pct":85,"this_scored_higher_than":753,"rank_type":"exact","sample_size":880,"percentile":85}}},"demographics":{"poster_types":{"member_of_the_public":1},"users":{"twitter":{"cohorts":{"Members of the public":1}}},"geo":{"twitter":{"US":1}}},"counts":{"total":{"posts_count":2},"news":{"unique_users_count":1,"unique_users":["ubm_medica"],"posts_count":1},"twitter":{"unique_users_count":1,"unique_users":["ClinicalLeader1"],"posts_count":1}},"posts":{"twitter":[{"url":"https:\/\/twitter.com\/ClinicalLeader1\/status\/517681837515472896","license":"datasift","citation_ids":[4691817],"posted_on":"2014-10-02T14:25:42+00:00","author":{"name":"Clinical Leader","url":"http:\/\/www.clinicalleader.com","image":"https:\/\/pbs.twimg.com\/profile_images\/621398529949478912\/ROqW2l0C_normal.png","description":"This is the Twitter account for Clinical Leader. Follow us to stay on top of the latest thoughts, advancements, and news in clinical trials.","id_on_source":"ClinicalLeader1","tweeter_id":"919426356","geo":{"lt":42.12922,"ln":-80.08506,"country":"US"},"followers":1490},"tweet_id":"517681837515472896"}],"news":[{"title":"Evofosfamide Fails to Extend Survival in Soft-Tissue Sarcoma, Pancreatic Cancer","url":"http:\/\/www.cancernetwork.com\/sarcoma\/evofosfamide-fails-extend-survival-soft-tissue-sarcoma-pancreatic-cancer","license":"public","citation_ids":[4691817],"posted_on":"2015-12-17T20:53:09+00:00","summary":"The developer of evofosfamide announced that two phase III trials of the agent in advanced soft-tissue sarcoma and in advanced pancreatic cancer did not meet their primary endpoints.","author":{"name":"UBM Medica","url":"http:\/\/mediakit.ubmmedica.com\/medical-resources","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/497\/normal\/Screen_Shot_2016-02-03_at_09.30.26.png?1454491836"}}]}}